Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VENUS CONCEPT INC.

(VERO)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
0.2650 USD   -8.62%
11/22Insider Buy: Venus Concept
MT
11/18Venus Concept Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/18Venus Concept Announces Completion of $6.72 Million Private Placement Financing
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Venus Concept Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10/06/2022 | 05:50pm EST

TORONTO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has issued a stock option inducement grant to its Chief Executive Officer, Rajiv De Silva, upon the execution of his employment agreement on October 2, 2022. The inducement grant was approved by a majority of the Company's independent directors in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement.

The inducement grant was made as a material inducement to Mr. De Silva’s acceptance of employment with the Company as a component of his employment compensation. It consists of stock options to purchase an aggregate of 3,300,000 shares of the Company's common stock. The inducement grant is subject to the terms and conditions of the award agreement covering the stock option grant. The options vest as follows: 25% vest on the one-year anniversary of the date of grant and the remaining 75% vest quarterly at a rate of 6.25% per quarter. The options have an exercise price of $0.44 per share, which is equal to the closing price of Company’s common stock on September 30, 2022.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 18 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS® and ARTAS iX® Robotic Hair Restoration systems. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about our financial performance; the growth in demand for our systems and other products; and general economic conditions, including the global economic impact of COVID-19, and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.


Investor Relations Contact:

ICR Westwicke on behalf of Venus Concept:

Mike Piccinino, CFA

VenusConceptIR@westwicke.com

Primary Logo

Source: Venus Concept Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about VENUS CONCEPT INC.
11/22Insider Buy: Venus Concept
MT
11/18Venus Concept Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equi..
AQ
11/18Venus Concept Announces Completion of $6.72 Million Private Placement Financing
AQ
11/18Venus Concept Inc. announced that it has received $6.72 million in funding from Essex W..
CI
11/10Venus Concept : Q3 Earnings Snapshot
AQ
11/10Transcript : Venus Concept Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10VENUS CONCEPT INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
11/10Earnings Flash (VERO) VENUS CONCEPT Reports Q3 Revenue $21.5M, vs. Street Est of $21.3M
MT
11/10Venus Concept Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
11/10Venus Concept Announces Third Quarter of Fiscal Year 2022 Financial Results
AQ
More news
Analyst Recommendations on VENUS CONCEPT INC.
More recommendations
Financials (USD)
Sales 2022 100 M - -
Net income 2022 -42,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,41x
Yield 2022 -
Capitalization 18,4 M 18,4 M -
Capi. / Sales 2022 0,18x
Capi. / Sales 2023 0,17x
Nbr of Employees 407
Free-Float 93,7%
Chart VENUS CONCEPT INC.
Duration : Period :
Venus Concept Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS CONCEPT INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,27 $
Average target price 2,17 $
Spread / Average Target 718%
EPS Revisions
Managers and Directors
Rajiv de Silva Chief Executive Officer & Director
Hermanth Jacob Varghese President & Chief Business Officer
Domenic Della Penna Chief Financial Officer
R. Scott Barry Chairman
Yoni Iger Vice President-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
VENUS CONCEPT INC.-82.94%20
THERMO FISHER SCIENTIFIC-17.49%216 935
DANAHER CORPORATION-19.35%193 165
INTUITIVE SURGICAL, INC.-25.88%94 110
BOSTON SCIENTIFIC CORPORATION6.92%64 683
SIEMENS HEALTHINEERS AG-25.17%57 995